Brands
01-05-2009 |
18:06 hs.
Biotechnology companies PDL BioPharma Inc. and Alexion Pharmaceuticals Inc., announced that they will jointly end lawsuit over humanized antibody monoclonal Soliris (eculizumab) patents, currently owned by Alexion and PDL's patents known as the “Queen”.
12-17-2008 |
14:42 hs.
12-02-2008 |
17:56 hs.
10-09-2008 |
11:18 hs.
10-08-2008 |
11:04 hs.
The Food and Drug Administration (FDA) has written a warning letter to Bayer AG about two television commercials featuring the company´s birth control pill Yaz, saying they give misleading impressions of the pill´s benefits and minimize the risks. Further details.
09-29-2008 |
09:17 hs.
AVANT Immunotherapeutics, Inc. announced that the Company will change its name to Celldex Therapeutics, Inc. effective October 1, 2008.
Erbitux patent
09-26-2008 |
13:13 hs.
Generics for 2010 and 2015
08-12-2008 |
11:46 hs.
Barr Pharmaceuticals, Inc. announced that its Barr Laboratories subsidiary has signed a settlement and a license agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim´s Mirapex, a treatment for first symptoms of Parkinson´s disease, and for Aggrenox, an anticoagulant. Further details.
06-18-2008 |
10:34 hs.
Five months later than Wall Street expected, Pfizer Inc and India’s generic drug maker Ranbaxy strike a settlement deal: Ranbaxy will be allowed to market its generic version of Pfizer’s cholesterol-lowering drug Lipitor in the U.S. by 2011, almost 20 months later than predicted
Orencia Patent Suit
04-08-2008 |
12:05 hs.
Massachusetts biotech Repligen settled a patent infringement lawsuit against New York’s Bristol-Myers Squibb over rheumatoid arthirtis treatment Orencia. Repligen will receive $5 million upfront, plus royalties that could exceed $30 million in fiscal 2009
$ 7.5 Million-Dollar Payment plus Royalties for Marketing
04-08-2008 |
09:30 hs.
Specialty pharmaceutical company Depomed Inc announced Teva Pharmaceuticals Ind. Ltd. unit Ivax Corp will be paying the company $ 7.5 million dollars for the settlement of a patent lawsuit. Further details.
Off-label uses of antipsychotics: children targeted
04-04-2008 |
12:28 hs.
The Justice Department accused New York-based Bristol-Myers and Otsuka American Pharmaceutical Inc of promoting the antipsychotic drug Abilify for use in children, and as a remedy for dementia, without regulatory approval. Bristol-Myers settled in September and Otsuka will now pay $4 million to resolve U.S. allegations
Irritable bowel syndrome drug
04-03-2008 |
07:59 hs.
03-18-2008 |
08:58 hs.
AstraZeneca will face next week the first of this year´s several generic threats to its antipsychotic Seroquel, as protection is set to end. Teva Pharmaceutical Industries probably will launch its own copy of the drug "at risk" once it obtains approval from the Food and Drug Administration. A trial against Teva and Sandoz (that is also seeking to sell copies of Seroquel), has been set for August 11.
Direct-to-Consumer Ads
02-26-2008 |
11:33 hs.
World number one U.S. drug maker Pfizer Inc. has voluntarily withdrawn cholesterol-lowering Lipitor direct-to-consumer ads and promotion featuring Dr. Robert Jarvik, well-known scientist and inventor of the artificial heart, who was part of Pfizer’s campaign to provide consumers with information about treating disease, according to the company. The ad campaign has been questioned by U.S. congressmen. Full story.
Patent Revoked
02-26-2008 |
10:21 hs.
The USPTO has rejected the validity of a key Genentech patent covering company’s method of producing drugs. The biotech company may appeal
La californiana considera la solicitud como muy inadecuada
02-03-2008 |
21:13 hs.
La suiza Roche Holding AG propuso a la norteamericana con sede en californiana AMGEN de pagar royalties por la venta de su droga aprobada para el tratamiento de la anemia Mircera. La biotecnológica rechazó de plano la propuesta.
